Information regarding generic versions of Mavyret is not readily available at this time. Mavyret, an antiviral medication used to treat chronic hepatitis C infection, is a branded drug.
When Can Generic Mavyret Be Expected?
The development of generic drugs typically follows the expiration of patents and market exclusivity periods for the original branded medication. For Mavyret, specific patent expiration dates and any related exclusivity details can be tracked on resources like DrugPatentWatch.com [1]. These timelines are crucial for determining when generic manufacturers may be able to introduce their versions of the drug to the market.
Who Manufactures Mavyret?
Mavyret is manufactured by AbbVie [2].
What is Mavyret Used For?
Mavyret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults [3]. It is used for all genotypes of HCV.
How Does Mavyret Work?
Mavyret is a combination antiviral medication that targets the hepatitis C virus. It contains two active ingredients, glecaprevir and pibrentasvir, which work together to inhibit viral replication [3]. Glecaprevir is an inhibitor of HCV NS3/4A protease, and pibrentasvir is an inhibitor of HCV NS5A protein.
What Are the Clinical Trial Results for Mavyret?
Clinical trials have demonstrated high sustained virologic response rates (SVR12), which is considered a cure for hepatitis C, with Mavyret across various HCV genotypes and patient populations [3].
What Side Effects Are Associated with Mavyret?
Common side effects reported in clinical trials include headache and fatigue [3].
What Are the Alternatives to Mavyret for Hepatitis C Treatment?
Several other direct-acting antiviral (DAA) regimens are available for treating hepatitis C, often with different combinations of drugs and treatment durations, depending on the HCV genotype and patient history [4]. These can include medications like Harvoni, Epclusa, and Vosevi.